Journal: PloS one

Article Title: Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium.

doi: 10.1371/journal.pone.0063702

Figure Lengend Snippet: Figure 1. The Expression of SELENBP1 in Normal and Tumor Breast Tissues. Breast cancer tissue arrays were stained by immunohistochemistry using anti-human SELENBP1 antibody at 1:100 dilution. Positive stained cells are shown in dark brown color. (A) Strong positive staining of SELENBP1 in normal breast tissue under low power view (200X). (B–C) Weak positive to negative staining of SELENBP1 in breast cancer tissues under high power view (400X). (D) The Allred scoring distributions of SELENBP1 expression in normal and tumor tissue groups. Inside lines represent means and standard deviations. *p,0.05. (E) Statistical results for the difference between normal and tumor tissues as analyzed by Kruskal-Wallis test. doi:10.1371/journal.pone.0063702.g001

Article Snippet: Breast Cancer Tissue Array Slides Three sets of breast cancer tissue arrays (including normal, primary tumor, and metastases) were obtained from Imgenex or Biomax Inc.

Techniques: Expressing, Staining, Immunohistochemistry, Negative Staining

Journal: PloS one

Article Title: Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium.

doi: 10.1371/journal.pone.0063702

Figure Lengend Snippet: Figure 2. SELENBP1 Expression is Progressively Reduced in Advancing Clinical Stages in Breast Cancer Tissues. (A) The scoring distributions of SELENBP1 expression in normal tissues and tumor tissues at stage II and stage III. Inside lines represent means and standard deviations. **p,0.01. (B) Statistical results for the difference between normal and tumor tissues as analyzed by Kruskal-Wallis test. (C) Survival curves of breast cancer patients with respect to different SELENBP1 expression levels are shown at stage II and (D) stage III. Blue and red lines represent the SELENBP1-high and SELENBP1-low groups, respectively. doi:10.1371/journal.pone.0063702.g002

Article Snippet: Breast Cancer Tissue Array Slides Three sets of breast cancer tissue arrays (including normal, primary tumor, and metastases) were obtained from Imgenex or Biomax Inc.

Techniques: Expressing

Journal: PloS one

Article Title: Reduced selenium-binding protein 1 in breast cancer correlates with poor survival and resistance to the anti-proliferative effects of selenium.

doi: 10.1371/journal.pone.0063702

Figure Lengend Snippet: Figure 3. The Correlation of SELENBP1 Expression with ER, PR, and TP53 in Breast Cancer Tissues. (A) The scoring distributions of SELENBP1 expression in normal tissues and tumor tissues with ER+ and ER– status. The inside lines represent means and standard deviations. **p,0.01. The difference between normal and ER+ and ER– tumor tissues was analyzed by Kruskal-Wallis test and statistical results are shown (B). Survival curves of breast cancer patients with respect to different SELENBP1 expression are shown in ER+ group in (C). The blue line is the SELENBP1- high group and the red line is the SELENBP1-low group. The scoring distributions of SELENBP1 expression in normal and tumor tissues with PR+/PR–

Article Snippet: Breast Cancer Tissue Array Slides Three sets of breast cancer tissue arrays (including normal, primary tumor, and metastases) were obtained from Imgenex or Biomax Inc.

Techniques: Expressing

Journal: Journal of Biological Chemistry

Article Title: Nectin-4, a New Serological Breast Cancer Marker, Is a Substrate for Tumor Necrosis Factor-α-converting Enzyme (TACE)/ADAM-17

doi: 10.1074/jbc.m410943200

Figure Lengend Snippet: FIG. 6. TACE expression in normal and tumor breast tissue samples. 20 g of tissue lysates were loaded and run on a 8% SDS- PAGE. Top, immunoblotting with anti-TACE pAb (1/1000) revealed two bands corresponding to the proform (120 kDa) and the active form (90 kDa) of TACE. Bottom, loading charge was controlled with an antibody directed against the p85 subunit of phosphatidylinositol 3-kinase (Up- state) used at 1/1000. N, normal breast tissues from three different donors; T, ductal breast carcinoma from six different patients. Note that tumor specimens used in this study were randomly selected. *, unde- fined band observed in some tumor samples with the anti-p85 pAb.

Article Snippet: Normal breast tissue lysates were purchased from ProSci and Abcam.

Techniques: Expressing, SDS Page, Western Blot

Journal: Scientific Reports

Article Title: NKX2 - 1-AS1 negatively regulates CD274 /PD-L1, cell-cell interaction genes, and limits human lung carcinoma cell migration

doi: 10.1038/s41598-018-32793-5

Figure Lengend Snippet: NKX2-1-AS1 expression patterns in human non-small cell lung carcinoma (NSCLC). ( A ) Schematic representation of the relative chromosomal location of NKX2-1-AS1 lncRNA and adjacent NKX2-1 protein coding-gene in human chromosomal region 14q13.3. Arrows indicate direction of transcription. Boxes indicate exons, dotted lines indicate introns and colored boxes indicate coding regions. ( B ) Levels of expression of NKX2-1-AS1 and NKX2-1 in NSCLCs (SCC = squamous cell carcinoma; and AC = adenocarcinoma) relative to their corresponding non-tumor control determined by qPCR (n = 8; * p < 0.03). ( C ) Correlation plot of the expression of NKX2-1-AS1 and NKX2-1 determined by qPCR in the above tumors and their corresponding non-tumor specimens analyzed in this study. ( D ) Amplification status of the NKX2-1-AS1 locus determined by qPCR of genomic DNA and expressed as copy number of the NKX2-1-AS1 gene per genome plotted relative to NKX2-1-AS1 expression level in each sample (n = 12).

Article Snippet: Genomic DNA corresponding to the tumors described in Table obtained from OriGene was used to determine the copy number of the NKX2-1-AS1 locus using a custom designed SYBR Green Assay (Supplementary Table .

Techniques: Expressing, Control, Amplification